Aktuelle Tagungsinformationen
News and Updates
Anmeldung zur Tagung
Registration
Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Collateral Events
Rahmenprogramm
Social program
Jubiläumsparty
Jubilee Party
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
DOG Homepage
Cyklophoto-versus Cyclocryocoagulation for the Treatment of Secondary Glaucoma
Korte P., Wirbelauer C., Häberle H., Pham D.-T.,
Vivantes Klinikum Neukölln, Klinik für Augenheilkunde (Berlin)
Purpose: Cyclophotocoagulation (CPC) is a recent alternative to cyclocryotherapy (CC) to decrease the intraocular pressure (IOP) in patients with secondary glaucoma.
Method: In this randomized prospective study 26 patients were treated by CPC (n=14) or CC (n=12). Changes in IOP, postoperative pain assessed with the visual analague scale (VAS), glaucomatous therapy and complications were recorded.
Results: In the CPC-group the mean preoperative IOP was 36,81±16,75 mmHg and in the CC-group 42,87±6,41 mmHg. Postoperatively the IOP decreased after 6 weeks to 18,5±5,02 mmHg (p=0,024) in the CPC-group and to 21,43±11,63 mmHg (p=0,018) in the CC-group. These values remained stable after 6 months with no significant differences between both groups. The mean postoperative pain values (VAS) were 4,705±4 in the CPC-group and 5,29±2,25 in the CC-group. In the CPC-group there were no complications, whereas in the CC-group two patients were retreated. Five patients required additional panretinal photocoagulation. No patient developed hypotonia.
Conclusions: The preliminary results of this ongoing randomized prospective study revealed that CPC and CC are equally effective in decreasing IOP by 50% in patients with secondary glaucoma.